ABSTRACT
BACKGROUND: After introducing Covid-19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration. METHODS: Databases were searched, covering a timeline from December 1, 2019 to February 28, 2022. Data were independently extracted and accessed for bias. SPSS statistical software version 25 was used for appropriate inferential statistics. RESULTS: Thirty-one studies were included for data extraction after screening following the eligibility criteria. A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea-like eruptions after vaccination, out of which 36 (55.38%) were female. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose. It was found popularly in the trunk area, either asymptomatically or with mild symptoms. Meantime the onset, was 8.58 days, and meantime it took to recover, was 6.44 weeks. CONCLUSION: The association between pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease.
Subject(s)
COVID-19 , Drug-Related Side Effects and Adverse Reactions , Pityriasis Rosea , Humans , Female , Adult , Middle Aged , Male , Pityriasis Rosea/epidemiology , Pityriasis Rosea/etiology , Pityriasis Rosea/diagnosis , COVID-19 Vaccines/adverse effects , COVID-19/epidemiology , VaccinationSubject(s)
COVID-19 , Exanthema , Pityriasis Rosea , COVID-19 Vaccines , Humans , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , VaccinationSubject(s)
Humans , Female , Adolescent , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , Remission, Spontaneous , Masks/adverse effectsABSTRACT
Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7. PR-like eruptions, which occur along with peripheral eosinophilia, interface dermatitis, and eosinophils on histopathology, may result from medications or vaccinations. Previously, PR-like eruptions had been noted following vaccination for influenza or other vaccines. During this pandemic, acute COVID-19 infection has been related to PR or PR-like eruptions in several cases. Various COVID-19 vaccines associated with PR-like eruptions were rarely reported. Herein, we report a case of cutaneous PR-like eruptions following COVID-19 mRNA-1273 vaccination.
Subject(s)
COVID-19 , Exanthema , Herpesvirus 6, Human , Pityriasis Rosea , 2019-nCoV Vaccine mRNA-1273 , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Humans , Pityriasis Rosea/etiology , Vaccination/adverse effectsABSTRACT
Pityriasis rosea (PR), PR-like eruptions (PR-LE), and herpes zoster have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination. PR is a self-limiting exanthematous disease and herpes zoster is a treatable condition; therefore, their occurrence does not require discontinuation of the vaccination schedule. PR-LE is a hypersensitivity reaction and is, therefore, less predictable in its course. In the case of a booster dose, the clinical manifestation may not recur, may be different from PR-LE, or may present with systemic symptoms; however, in the case of PR-LE, the possibility of mild and predominantly cutaneous adverse events should not discourage all eligible candidates from receiving and completing the COVID-19 vaccination program, as such adverse reactions represent a small risk considering the possible severe and fatal outcome of COVID-19. We emphasize the relevance of looking for any viral reactivation in patients infected with SARS-CoV-2 who have skin eruptions. The search for viral reactivations could be useful not only for distinguishing between PR and PR-LE but also because viral reactivations may contribute to a patient's systemic inflammation and influence the course of the disease.
Subject(s)
COVID-19 Vaccines , COVID-19 , Exanthema , Herpes Zoster , Pityriasis Rosea , Humans , COVID-19/complications , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Exanthema/complications , Herpes Zoster/complications , Pandemics , Pityriasis Rosea/etiology , SARS-CoV-2ABSTRACT
Dear Editor, Pityriasis rosea (PR) is a common, self-limited erythematous papulosquamous dermatosis that mainly affects young adults. It is believed to represent a delayed reaction to viral infections and is usually associated with endogenous systemic reactivation of human herpesvirus (HHV) 6 and / or 7 (1). A 46-year-old man presented to our Department with a two-week history of skin rash associated with mild pruritus. He described the appearance of an erythematous centrally scaled lesion at the right part of his abdomen, followed by the spreading of red oval mildly scaling lesions on the trunk, neck, and proximal parts of the upper extremities, which showed in the physical examination (Figure 1, a and b). He was otherwise healthy and taking no medications. Six weeks prior to the appearance of the initial skin lesion, the patient had coronavirus disease 2019 (COVID-19) infection with mild clinical presentation (fever up to 38 °C lasting for four days and mild headache) and with symptoms of post COVID-19 syndrome (excessive tiredness). He denied oropharyngeal lesions. Potassium hydroxide, syphilis, and laboratory tests were within normal limits. Within two weeks of topical betamethasone dipropionate treatment, the lesions disappeared completely. In addition to reactivation of HHV-6 or HHV-7, PR can be triggered by some drugs (like angiotensin-converting enzyme inhibitors alone or in combination with hydrochlorothiazide, sartans plus hydrochlorothiazide, allopurinol, nimesulide, and acetyl salicylic acid (2) and vaccines (such as smallpox, poliomyelitis, influenza, human papillomavirus, diphtheria, tuberculosis, hepatitis B, pneumococcus, and yellow fever vaccines) (3). There is a growing number of published cases that link PR to COVID-19 infection, with PR appearing either in the acute phase of COVID-19 or, as in our patient, in the post COVID-19 period (4-9). Unlike in our patient, oropharyngeal lesions were observed in approximately 16% of patients with typical PR (10). It has been suggested that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces reactivation of other viruses, such as HHV-6, HHV-7, varicella zoster virus, and Epstein-Barr virus (5). PR has also been reported to follow COVID-19 vaccination (11). As our patient did not receive a COVID-19 vaccine, we cannot evaluate the latter based on the present case. We speculate that PR could be a delayed skin manifestation of COVID-19 infection, triggered either by SARS-CoV-2 immediately or indirectly by the reactivation of other viruses such as HHV-6 or HHV-7. However, the etiopathogenetic mechanisms remain largely unknown and further studies are needed in order to clarify the correlation between SARS-CoV-2 and PR.
Subject(s)
COVID-19 , Epstein-Barr Virus Infections , Herpesvirus 6, Human , Herpesvirus 7, Human , Pityriasis Rosea , Male , Young Adult , Humans , Middle Aged , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , Pityriasis Rosea/pathology , COVID-19 Vaccines , COVID-19/complications , Post-Acute COVID-19 Syndrome , SARS-CoV-2 , Herpesvirus 4, Human , Herpesvirus 7, Human/physiology , HydrochlorothiazideSubject(s)
Pityriasis Rosea , Vaccines , 2019-nCoV Vaccine mRNA-1273 , Humans , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , SkinSubject(s)
COVID-19 , Exanthema , Pityriasis Rosea , COVID-19 Vaccines , Humans , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , SARS-CoV-2ABSTRACT
Cutaneous findings have increasingly been reported in patients with coronavirus disease 2019 (COVID-19). This review discusses associated skin findings in patients with COVID-19 in the inpatient setting, ranging from vasculopathy-related lesions associated with high hospitalization rate and poor prognosis to inflammatory vesicular and urticarial eruptions that are rarely associated with prolonged hospitalization. We also discuss other reported COVID-19 cutaneous manifestations such as Sweet's syndrome, purpuric eruptions, and Multisystem Inflammatory Syndrome in Children. Although the relationship between dermatologic changes and COVID-19 disease progression is not fully elucidated, familiarity with cutaneous manifestations is valuable for physicians caring for patients hospitalized with COVID-19 and may help improve disease recognition and care.
Subject(s)
COVID-19/complications , COVID-19/diagnosis , Inpatients/statistics & numerical data , Skin Diseases/diagnosis , Skin Diseases/etiology , Systemic Inflammatory Response Syndrome/complications , Systemic Inflammatory Response Syndrome/diagnosis , Adult , COVID-19/pathology , Chilblains/diagnosis , Chilblains/etiology , Child , Exanthema/diagnosis , Exanthema/etiology , Humans , Pityriasis Rosea/diagnosis , Pityriasis Rosea/etiology , Skin Diseases, Vascular/diagnosis , Skin Diseases, Vascular/etiology , Systemic Inflammatory Response Syndrome/pathology , Urticaria/diagnosis , Urticaria/etiologySubject(s)
COVID-19 , Pityriasis Rosea , COVID-19 Vaccines , Humans , Pityriasis Rosea/etiology , SARS-CoV-2 , VaccinationSubject(s)
COVID-19 , Pityriasis Rosea , COVID-19 Vaccines , Humans , Pityriasis Rosea/etiology , SARS-CoV-2 , Vaccination/adverse effectsABSTRACT
RATIONALE: Pityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PATIENT CONCERNS: We present the case of a female patient in whom the diagnosis of pityriasis rosea led to the investigation and diagnosis of the SARS-CoV-2 infection. The patient presented to the Department of Dermatology for a 3âweek duration of an extremely pruritic erythematous-squamous lesion, initially on the trunk and upper limbs, with extension to the lower limbs in the last week and the lesion respected the cephalic extremity, palms, and soles. One week before the rash, respiratory tract infection symptomatology was observed by the patient. At home, she underwent systemic treatment with antihistamines and topical medication with dermatocorticosteroids. The evolution was unfavorable, with the spread of the lesions and the accentuation of the pruritus. DIAGNOSES: Considering the actual epidemiological context, we performed a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay from nasal and pharyngeal swabs for coronavirus disease 2019 (COVID-19) to investigate the PR etiology. The patient had a positive RT-PCR result, and was confirmed with SARS-CoV-2 infection. INTERVENTIONS: Treatment was initiated with systemic corticosteroid therapy - hydrocortisone hemisuccinate 200âmg/day for 7âdays, and loratadine 10âmg 2 times a day. Also, topical medication with dermatocorticosteroids and emollients was associated. OUTCOME: Under the treatment that was initiated a partial remission of the lesions after 7âdays was observed. LESSONS: Our reported case adds to the other findings regarding the association of PR with SARS-CoV-2 infection, in the context of the pandemic, suggesting the need to test patients with PR skin lesions for SARS-CoV-2 infection.
Subject(s)
COVID-19/complications , Pityriasis Rosea/etiology , Adrenal Cortex Hormones/therapeutic use , Female , Humans , Middle Aged , Pityriasis Rosea/drug therapy , Pityriasis Rosea/virology , SARS-CoV-2ABSTRACT
No disponible
Subject(s)
Humans , Female , Young Adult , Pityriasis Rosea/etiology , Asymptomatic Diseases , Betacoronavirus , Coronavirus Infections/diagnosis , Coronavirus Infections/transmission , Pneumonia, Viral/diagnosis , Pneumonia, Viral/transmission , Pneumonia, Viral/physiopathology , Coronavirus Infections/physiopathology , Erythema/etiologyABSTRACT
Pityriasis Rosea (PR) and labyrinthitis are most commonly caused by viral infections. PR presents with a characteristic rash while labyrinthitis presents with vertigo, tinnitus and hearing loss. However, the coexistence of PR and Labyrinthitis remains an uncommon event. Human Herpes Virus (HHV) 6 and 7, are common infections in childhood, and their reactivation causes Pityriasis Rosea. But these viruses are not known to have any involvement with the inner ear or the 8th cranial nerve (CN).
Subject(s)
Herpesvirus 6, Human , Herpesvirus 7, Human , Labyrinthitis/virology , Pityriasis Rosea/virology , Roseolovirus Infections/complications , Emergency Service, Hospital , Humans , Labyrinthitis/etiology , Male , Middle Aged , Pityriasis Rosea/etiology , Roseolovirus Infections/diagnosis , Roseolovirus Infections/virologyABSTRACT
Any infectious illness presenting with an eruption in a pregnant patient may be associated with an increased risk of fetal loss. The viruses that can infect the placenta during maternal infection and can be transmitted to the fetus and cause congenital disease include the rubella virus, the measles virus, the varicella zoster virus, parvovirus B19, human cytomegalovirus, arboviruses, and hepatitis E virus type 1. In addition, some bacteria responsible for exanthematous diseases, like Treponema pallidum, can be transmitted during pregnancy from the mother to the fetus and cause fetal loss. All these infectious agents can cause typical and/or atypical exanthems whose etiologic diagnosis is sometimes difficult but important to determine, especially in pregnant women because of the potential risk to the fetus. In the last 20 years, we have extensively studied pityriasis rosea from the clinical and laboratory perspectives, demonstrating the pathogenic role of human herpesvirus (HHV)-6 and -7. We synthesize the available evidence that PR may be associated with active HHV-6/7 infection and therefore with complications during pregnancy and fetal loss. We have also summarized the emerging infectious illnesses of dermatologic interest that may represent life-threatening health conditions for the fetus: measles, rubella, arbovirus infection, and syphilis.
Subject(s)
Bacterial Infections/complications , Infectious Disease Transmission, Vertical , Pityriasis Rosea/etiology , Pityriasis Rosea/pathology , Pregnancy Complications, Infectious/etiology , Pregnancy Complications/etiology , Pregnancy Complications/pathology , Skin/pathology , Virus Diseases/complications , Female , Herpesvirus 6, Human , Humans , Pregnancy , Roseolovirus Infections/complicationsABSTRACT
Pityriasis rosea (PR) is an acute self-limited exanthem characterized by oval erythematous patches with scale and may be difficult to differentiate from secondary syphilis. A rapid plasma reagin (RPR) test can be used to rule in secondary syphilis with high sensitivity and specificity. A retrospective study was performed on patients at Weill Cornell Medicine, who were diagnosed with PR from 2000 to 2016 and also received RPR testing at the time of diagnosis. The objective was to assess the frequency of secondary syphilis when the initial clinical impression was PR. Only 2/142 patients (1.4%) had a reactive RPR test. Based on our results, we advocate that careful social and sexual histories be taken in all patients presenting with atypical PR and syphilis screening performed if risk factors are present.
Subject(s)
Pityriasis Rosea/diagnosis , Reagins/blood , Syphilis Serodiagnosis/methods , Syphilis/epidemiology , Adult , Antibodies, Bacterial/blood , Female , Humans , Immunologic Factors , Male , Middle Aged , Pityriasis Rosea/etiology , Retrospective Studies , Sensitivity and Specificity , Syphilis/diagnosis , Treponema pallidum/immunologyABSTRACT
A switch from cell-mediated to humoral immunity (helper T 1 [Th1] to helper T 2 [Th2] shift) during gestation plays a key role in placental immune tolerance. As a result, skin diseases that are Th2 mediated often worsen, whereas skin diseases that are Th1 mediated often improve during gestation. Also, due to fluctuations in glandular activity, skin diseases involving sebaceous and eccrine glands may flare, whereas those involving apocrine glands may improve during pregnancy. Despite these trends, inflammatory and glandular skin diseases do not always follow the predicted pattern, and courses are often diverse. We review the gestational course of inflammatory skin diseases, such as atopic dermatitis (atopic eruption of pregnancy), psoriasis, impetigo herpetiformis, urticaria, erythema annulare centrifugum, pityriasis rosea, sarcoidosis, Sweet syndrome, and erythema nodosum, as well as glandular skin diseases, including acne vulgaris, acne rosacea, perioral dermatitis, hidradenitis suppurativa, Fox-Fordyce disease, hyperhidrosis, and miliaria. For each of these diseases, we discuss the pathogenesis, clinical presentation, and management with special consideration for maternal and fetal safety.